ANAB vs FOLD vs RARE vs KRYS

For growth investors, AnaptysBio, Inc.

(ANAB) is the stronger pick with 157. 0% revenue growth year-over-year, versus 20. 0% for Amicus Therapeutics, Inc. (FOLD). Krystal Biotech, Inc. (KRYS) offers the better valuation at 44. 7x trailing P/E (39. 4x forward), making it the more compelling value choice. Analysts rate AnaptysBio, Inc. (ANAB) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Krystal Biotech, Inc.

is actually cheaper at 39. 4x.

Over the past 5 years, Krystal Biotech, Inc.

(KRYS) delivered a total return of +364. 0%, compared to -76. 1% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: KRYS returned +27. 7% versus RARE's -59. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.

(FOLD) is the lower-risk stock at 0. 61β versus Ultragenyx Pharmaceutical Inc. 's 1. 36β — meaning RARE is approximately 123% more volatile than FOLD relative to the S&P 500. On balance sheet safety, Krystal Biotech, Inc. (KRYS) carries a lower debt/equity ratio of 1% versus 176% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AnaptysBio, Inc.

(ANAB) is pulling ahead at 157. 0% versus 20. 0% for Amicus Therapeutics, Inc. (FOLD). On earnings-per-share growth, the picture is similar: Krystal Biotech, Inc. grew EPS 128. 0% year-over-year, compared to 7. 3% for Ultragenyx Pharmaceutical Inc.. Over a 3-year CAGR, ANAB leads at 183. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Krystal Biotech, Inc.

(KRYS) is the more profitable company, earning 52. 6% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 52. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KRYS leads at 41. 5% versus -79. 5% for RARE. At the gross margin level — before operating expenses — ANAB leads at 99. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Krystal Biotech, Inc.

(KRYS) trades at 39. 4x forward P/E versus 40. 6x for Amicus Therapeutics, Inc. — 1. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RARE: 85. 1% to $48. 36.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Amicus Therapeutics, Inc.

(FOLD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 61), +119. 2% 10Y return). Both have compounded well over 10 years (FOLD: +119. 2%, RARE: -59. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.